Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
This page provides access to the complete catalogue of MARA Ratings® — independent, committee-reviewed Reimbursement Risk Assessments designed for high-stakes Pharma Market Access decisions across therapeutic areas, indications, and launch stages.
Each listing represents a standardized Reimbursement Risk Assessment, calibrated against historical Health Technology Assessment (HTA) decisions and real-world payer outcomes across the US, EU4, UK, and Japan. The framework aligns clinical evidence, cost-effectiveness, and quality-of-life impact within a structured Pharma Market Access risk model.
MARA Ratings are not opinions.
They are structured, evidence-linked Reimbursement Risk Assessments that reduce variance in pricing, reimbursement, and market access assumptions before major capital allocation, licensing, M&A, or launch commitments are made.